Polycystic ovary syndrome classification: Difference between revisions
No edit summary |
Irfan Dotani (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Polycystic ovary syndrome}} | {{Polycystic ovary syndrome}} | ||
{{CMG}}; {{AE}} | |||
{{ | {{PleaseHelp}} | ||
==Overview== | ==Overview== | ||
Line 18: | Line 19: | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Gynecology]] | [[Category:Gynecology]] | ||
[[Category:Obstetrics]] | [[Category:Obstetrics]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 12:11, 21 July 2016
Polycystic ovary syndrome Microchapters |
Differentiating Polycystic ovary syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Polycystic ovary syndrome classification On the Web |
American Roentgen Ray Society Images of Polycystic ovary syndrome classification |
Risk calculators and risk factors for Polycystic ovary syndrome classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Classification
Two definitions are commonly used:
- In 1990 a consensus workshop sponsored by the NIH/NICHD suggested that a patient has PCOS if she has (1) signs of androgen excess (clinical or biochemical), (2) oligoovulation, and (3) other entities are excluded that would cause polycystic ovaries.
- In 2003 a consensus workshop sponsored by ESHRE/ASRM in Rotterdam indicated PCOS to be present if 2 out of 3 criteria are met: (1) oligoovulation and/or anovulation, (2) excess androgen activity, (3) polycystic ovaries (by gynecologic ultrasound), and other causes of PCOS are excluded.
The Rotterdam definition is wider, including many more patients, notably patients without androgen excess, whereas in the NIH/NICHD definition androgen excess is a prerequisite. Critics maintain that findings obtained from the study of patients with androgen excess cannot necessarily be extrapolated to patients without androgen excess.